Authored By: Sarah
11 Jul 2024

 Transfection Technologies Market Size to grow by USD 675.9 million between 2024-2028

According to a research report “ Transfection Technologies Market” by Type (Viral-vector based transfection, Physical transfection, Biochemical based transfection) End-user (Pharmaceutical and biotechnology companies, Contract research organizations, Academic and research institutes) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 675.9 million, at a CAGR of  9.66% during the forecast period. In the pharmaceutical industry, monoclonal antibodies, which are identical immune cells, are experiencing significant demand due to their diverse applications in biology, diagnostic imaging, medicine, and biochemistry. These applications span various medical fields, including cancer, multiple sclerosis, rheumatoid arthritis, cardiovascular diseases, Crohn's disease, psoriasis, and ulcerative colitis. With the escalating prevalence of chronic diseases and the resulting need for antibiotic treatments, the demand for monoclonal antibodies continues to increase. To meet this demand, large manufacturers have established large-scale production facilities equipped with multiple cell culture bioreactors for antibody production.

Browse market data tables, figures, and in-depth TOC on “Transfection Technologies Market” by Type (Viral-vector based transfection, Physical transfection, Biochemical based transfection) End-user (Pharmaceutical and biotechnology companies, Contract research organizations, Academic and research institutes) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Type, the Viral-vector based transfection segment is projected to dominate the market size in 2024

In the pharmaceutical and biotechnology industry, the demand for transfection technologies is escalating due to the increasing incidence of chronic diseases and the subsequent requirement for the production of advanced, regulatory-compliant therapeutics. Transfection technologies enable the efficient and cost-effective delivery of plasmid DNA pharmaceuticals, providing a significant advantage during the drug development process. These technologies are instrumental in creating cell-based assays, disease models, and preclinical screening platforms, making them indispensable tools for pharmaceutical and biotechnology companies. The benefits of transfection technologies, including speed, robustness, and high delivery efficiency, ensure their continued relevance in this sector throughout the forecast period.

By End-user, Pharmaceutical and biotechnology companies  segment is expected to hold the largest market size for the year 2024

In the realm of transfection technologies, viral vector-based methods have gained significant traction due to their high efficiency and capability to induce stable and enduring transgene expression in target cells. Utilizing viral vectors, such as lentivirus, adenovirus, adeno-associated virus (AAV), and retrovirus, these techniques facilitate the delivery of nucleic acids into cells with remarkable success. This efficacy stems from the ability of viral vectors to penetrate cell membranes and integrate transgenes into the host genome, resulting in sustained gene expression over extended periods. The versatility of viral vector-based transfection methods makes them indispensable for various research and clinical applications, particularly those requiring high levels of gene expression or long-term transgene integration.

North America is forecasted to hold the largest market size by region in 2024

ai_geographic_landscape

The Transfection Technologies Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Altogen Biosystems
  • Bio Rad Laboratories Inc.
  • Danaher Corp.
  • F. Hoffmann La Roche Ltd.
  • GENLANTIS
  • ibidi GmbH
  • Inovio Pharmaceuticals Inc.
  • Kytopen Corp.
  • Life Technologies India Pvt Ltd.
  • Lonza Group Ltd.
  • MaxCyte Inc.
  • Merck KGaA
  • Mirus Bio LLC
  • OZ Biosciences
  • Promega Corp.
  • QIAGEN NV
  • RJH BIOSCIENCES
  • Sartorius AG
  • SignaGen Laboratories
  • STEMCELL Technologies Inc.
  • Takara Holdings Inc.
  • Thermo Fisher Scientific Inc.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Transfection technologies market encompasses a range of techniques used to introduce nucleic acids, including DNA and RNA, into cells for various applications in biomedical research and therapeutic delivery. Key components of transfection technologies include selection techniques, reporter gene systems, and gene transfection methods. Reporter genes enable the monitoring of gene expression, while selection techniques facilitate the identification of transfected cells. RNA interference (RNAi) and miRNA are emerging transfection technologies that utilize small RNA molecules to silence specific genes. Nucleic acids can be delivered using various methods, including viral vectors, electroporation, and lipid-mediated transfection. Drug delivery and therapeutic delivery systems are also critical components of the transfection technologies market, as they enable the efficient delivery of therapeutic agents for the treatment of chronic diseases, such as cancer, heart disease, and genetic disorders. The incidence of cancer and other diseases continues to drive the demand for advanced transfection technologies in cell-based therapies and gene therapy. The HEK293 cell line and oligonucleotides are commonly used in transfection experiments, while Ribonucleic Acid (RNA) and Deoxyribonucleic Acid (DNA) are the primary nucleic acids used in these applications. The transfection technologies market is expected to grow significantly in the coming years due to the increasing demand for advanced therapeutic and diagnostic tools.

Market Research Overview

The transfection technologies market encompasses a range of techniques used to introduce nucleic acids, including DNA, RNA, miRNA, and oligonucleotides, into cells for various applications in cancer diagnostics, drug delivery, therapeutic delivery systems, and biomedical research. These applications include the detection of proteomic, genetic, and epigenetic biomarkers for HIV, obesity, and chronic diseases such as cancer, heart disease, and genetic disorders. Selection techniques, reporter gene systems, and viral vector transfection are commonly used methods for gene transfection. Physical transfection methods, such as electroporation and lipofection, are also widely used. Transfection technologies have significant implications for personalized medicine, protein production, and therapeutic delivery, particularly in the context of RNA interference (RNAi) and gene therapy. Investments and fundings in transfection technologies have been increasing due to their potential applications in cancer diagnostics, drug discovery, and cell-based therapies. Collaborative networks between regulatory authorities, technology providers, and research institutions are driving advancements in this field. However, challenges such as cytotoxicity and safety concerns must be addressed to ensure the successful translation of these technologies into clinical applications. Key players in the transfection technologies market include Thermo Fisher Scientific, Invitrogen, and Transfectimax Systems. The market is expected to grow significantly in the coming years due to the increasing incidence of cancer and other chronic diseases, as well as the potential for personalized medicine and cell-based therapies.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio